melagatran has been researched along with Hemorrhage in 12 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 10 (83.33) | 29.6817 |
| 2010's | 1 (8.33) | 24.3611 |
| 2020's | 1 (8.33) | 2.80 |
| Authors | Studies |
|---|---|
| Pilgram, O; Steinmetzer, T; Wenzel, BM; Wiedemeyer, SJA | 1 |
| Bergmann, JF; Lloret Linares, C | 1 |
| Agnelli, G; Cohen, AT; Dahl, OE; Eriksson, BI; Eskilson, C; Frison, L; Mouret, P; Nylander, I; Ogren, M; Rosencher, N | 1 |
| Carlsson, S; Johnston, M; Klement, P; Liao, P; Rak, J; Stafford, A; Vlasin, M; Weitz, JI | 1 |
| Eriksson, UG; Johansson, S; Larson, G; Larsson, M; Ohlsson, L; Wåhlander, K | 1 |
| Agnelli, G; Andersson, M; Cohen, AT; Dahl, OE; Eriksson, BI; Eskilson, C; Freij, A; Kälebo, P; Lassen, MR; Mouret, P; Panfilov, S; Rosencher, N | 1 |
| Bijsterveld, NR; Keller, TT; Levi, M | 1 |
| Carlsson, S; Elg, M | 1 |
| Carlsson, S; Elg, M; Gustafsson, D | 1 |
| Bode, C; Darius, H; Diehm, C; Encke, A; Gulba, DC; Haas, S; Hacke, W; Puhl, W; Quante, M; Riess, H; Scharf, R; Schellong, S; Schrör, T; Schulte, KL; Tebbe, U; Van Aken, H | 1 |
| Fiessinger, JN | 1 |
| Ahnfelt, L; Arfwidsson, AC; Björkström, S; Elvander, CS; Eriksson, BI; Eriksson, UG; Folestad, A; Frison, L; Kälebo, P; Ogren, M; Sjöstedt, A | 1 |
3 review(s) available for melagatran and Hemorrhage
| Article | Year |
|---|---|
Recombinant factor VIIa as an antidote for anticoagulant treatment.
Topics: Anticoagulants; Azetidines; Benzylamines; Factor VII; Factor VIIa; Glycine; Helminth Proteins; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Recombinant Proteins | 2004 |
Anticoagulation: the present and future.
Topics: Administration, Oral; Amino Acid Chloromethyl Ketones; Anticoagulants; Arginine; Azetidines; Benzylamines; Binding Sites; Biological Availability; Blood Coagulation; Comorbidity; Coumarins; Drug Design; Embolism; Female; Forecasting; Glycine; Guanidines; Heart Diseases; Hemorrhage; Heparin; Heparin, Low-Molecular-Weight; Hirudin Therapy; Humans; Neoplasms; Pipecolic Acids; Pregnancy; Pregnancy Complications, Hematologic; Prodrugs; Safety; Serine; Stroke; Sulfonamides; Thrombin; Thrombophilia; Thrombosis | 2001 |
[Treatment of deep vein thrombosis. Current and future questions].
Topics: Administration, Oral; Anticoagulants; Azetidines; Benzylamines; Glycine; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; Polysaccharides; Recurrence; Risk Factors; Venous Thrombosis | 2001 |
4 trial(s) available for melagatran and Hemorrhage
| Article | Year |
|---|---|
Direct thrombin inhibitor melagatran followed by oral ximelagatran in comparison with enoxaparin for prevention of venous thromboembolism after total hip or knee replacement.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Azetidines; Benzylamines; Cause of Death; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Glycine; Hemorrhage; Humans; Injections, Subcutaneous; Male; Middle Aged; Postoperative Complications; Prodrugs; Prospective Studies; Pulmonary Embolism; Safety; Thrombin; Treatment Outcome; Venous Thrombosis | 2003 |
Pharmacokinetics and anticoagulant effect of the direct thrombin inhibitor melagatran following subcutaneous administration to healthy young men.
Topics: Adult; Anticoagulants; Area Under Curve; Azetidines; Benzylamines; Biological Availability; Blood Coagulation; Blood Coagulation Tests; Dose-Response Relationship, Drug; Glycine; Half-Life; Hemorrhage; Humans; Injections, Subcutaneous; Male; Pharmacokinetics; Thrombin | 2003 |
The direct thrombin inhibitor melagatran followed by oral ximelagatran compared with enoxaparin for the prevention of venous thromboembolism after total hip or knee replacement: the EXPRESS study.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Azetidines; Benzylamines; Double-Blind Method; Enoxaparin; Female; Glycine; Hemorrhage; Humans; Male; Middle Aged; Preoperative Care; Therapeutic Equivalency; Thrombin; Thromboembolism; Venous Thrombosis | 2003 |
Prophylaxis of venous thromboembolism with subcutaneous melagatran in total hip or total knee replacement: results from Phase II studies.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Azetidines; Benzylamines; Cyclodextrins; Female; Fibrinolytic Agents; Glycine; Hemorrhage; Humans; Injections, Subcutaneous; Male; Middle Aged; Partial Thromboplastin Time; Phlebography; Thromboembolism; Venous Thrombosis | 2002 |
5 other study(ies) available for melagatran and Hemorrhage
| Article | Year |
|---|---|
Fibrinolysis Inhibitors: Potential Drugs for the Treatment and Prevention of Bleeding.
Topics: Animals; Antifibrinolytic Agents; Catalytic Domain; Crystallography, X-Ray; Fibrinolysin; Fibrinolysis; Hemorrhage; Humans; Ligands; Molecular Structure; Plasminogen; Protein Binding; Protein Domains | 2020 |
[Story of a predictable death: the end of vitamin K antagonists?].
Topics: Anticoagulants; Azetidines; Benzylamines; France; Hemorrhage; Humans; Pulmonary Embolism; Thromboembolism; Thrombosis; Venous Thrombosis; Vitamin K | 2010 |
The benefit-to-risk profile of melagatran is superior to that of hirudin in a rabbit arterial thrombosis prevention and bleeding model.
Topics: Animals; Arteries; Azetidines; Benzylamines; Dose-Response Relationship, Drug; Fibrin; Fibrinolytic Agents; Glycine; Hemorrhage; Hirudin Therapy; Hirudins; Male; Rabbits; Risk Assessment; Thrombin; Thrombosis | 2003 |
The effects of ximelagatran and warfarin on the prophylaxis of a caval vein thrombosis and bleeding in the anaesthetized rat.
Topics: Animals; Azetidines; Benzylamines; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Glycine; Hemorrhage; Male; Rats; Rats, Sprague-Dawley; Venae Cavae; Venous Thrombosis; Warfarin | 2005 |
Effects of agents, used to treat bleeding disorders, on bleeding time prolonged by a very high dose of a direct thrombin inhibitor in anesthesized rats and rabbits.
Topics: Animals; Anticoagulants; Azetidines; Benzylamines; Bleeding Time; Blood Coagulation Factors; Factor IX; Factor VIIa; Factor VIII; Glycine; Hemorrhage; Humans; Rabbits; Rats; Thrombin; von Willebrand Factor | 2001 |